

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 13, 2021**

**FibroGen, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36740**  
(Commission  
File Number)

**77-0357827**  
(IRS Employer  
Identification No.)

**FibroGen, Inc.**  
**409 Illinois Street**  
**San Francisco, CA 94158**  
(Address of principal executive offices, including zip code)

**(415) 978-1200**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

<b>Title of each class</b>	<b>Trading Symbol</b>	<b>Name of each exchange on which registered</b>
Common Stock, \$0.01 par value	FGEN	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01 Entry into a Material Definitive Agreement.**

On January 13, 2021, FibroGen, Inc. (“FibroGen”) entered into a supply agreement (the “EU Supply Agreement”) with Astellas Pharma Europe Ltd. (“Astellas”), pursuant to which FibroGen will supply roxadustat as bulk drug product to Astellas for commercial and other uses in Europe, the Commonwealth of Independent States, the Middle East, and South Africa under the Anemia License and Collaboration Agreement entered into between FibroGen and Astellas, effective April 28, 2006 (the “Collaboration Agreement”). The EU Supply Agreement contains delivery, acceptance, payment, termination, forecasting, and other terms consistent with the Collaboration Agreement, as well as certain quality assurance, indemnification, liability and other standard industry terms.

The foregoing description of the EU Supply Agreement is not a complete description thereof, and is qualified in its entirety by reference to the full text of the EU Supply Agreement, which will be filed with the Securities and Exchange Commission as an exhibit to FibroGen’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2021.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 26, 2021

**FIBROGEN, INC.**

By: /s/ Michael Lowenstein

Michael Lowenstein  
Chief Legal Officer